Related Experiment Video
Updated: Jul 27, 2025
Isolation and Characterization of Dendritic Cells and Macrophages from the Mouse Intestine
Published on: May 21, 2012
SENP2 restrains the generation of pathogenic Th17 cells in mouse models of colitis
Tsan-Tzu Yang1,2, Ming-Feng Chiang2, Che-Chang Chang3
1Graduate Institute of Immunology, College of Medicine, National Taiwan University, Taipei, 10002, Taiwan.
Abstract:
The molecular mechanisms contributing to the regulation of Th17-mediated inflammation remain underexplored. We here report a SUMO-specific protease (SENP)2-mediated pathway induced in pathogenic Th17 cells that restricts the pathogenesis of inflammatory colitis. SENP2 regulates the maturation of small ubiquitin-like modifiers (SUMO) and recycles SUMO from the substrate proteins. We find higher levels of SENP2 in pathogenic Th17 cells. By deleting Senp2 in T-cell lineages in mice, we demonstrate that the lack of Senp2 exacerbates the severity of experimental colitis, which is linked to elevated levels of GM-CSF+IL-17A+ pathogenic Th17 cells and more severe dysbiosis of the intestinal microbiome. Adoptive transfer experiments demonstrate the cell-autonomous effect of Senp2 in restraining Th17 differentiation and colitis. The enzymatic activity of SENP2 is important for deSUMOylation of Smad4, which reduces Smad4 nuclear entry and Rorc expression. Our findings reveal a SENP2-mediated regulatory axis in the pathogenicity of Th17 cells.
Insights
SUMO-specific protease 2 (SENP2) restricts inflammatory colitis by regulating pathogenic Th17 cells. Loss of SENP2 increases GM-CSF+IL-17A+ Th17 cells, exacerbating disease severity and gut microbiome dysbiosis.
Area of Science:
- Immunology
- Molecular Biology
- Gastroenterology
Background:
- Th17-mediated inflammation is crucial in autoimmune diseases but its regulation is not fully understood.
- Pathogenic Th17 cells contribute significantly to inflammatory conditions like colitis.
- Small ubiquitin-like modifier (SUMO)ylation pathways are implicated in immune cell function.
Purpose of the Study:
- To investigate the role of SUMO-specific protease 2 (SENP2) in regulating pathogenic Th17 cell function.
- To elucidate the molecular mechanisms by which SENP2 influences Th17-mediated inflammation and inflammatory colitis.
- To determine the therapeutic potential of targeting SENP2 in inflammatory conditions.
Main Methods:
- Generated mice with T-cell specific deletion of Senp2.
- Analyzed Th17 cell populations (GM-CSF+IL-17A+) and gut microbiome composition in experimental colitis models.
- Performed adoptive transfer experiments to assess cell-autonomous effects.
- Investigated the deSUMOylation activity of SENP2 on Smad4 and its impact on nuclear entry and Rorc expression.
Main Results:
- SENP2 levels are elevated in pathogenic Th17 cells.
- Senp2 deletion in T cells exacerbates experimental colitis severity.
- Lack of SENP2 leads to increased GM-CSF+IL-17A+ pathogenic Th17 cells and gut dysbiosis.
- SENP2 enzymatic activity is essential for deSUMOylating Smad4, reducing its nuclear entry and Rorc expression, thereby restraining Th17 differentiation and colitis.
Conclusions:
- SENP2 acts as a critical negative regulator of pathogenic Th17 cell differentiation and function.
- A SENP2-mediated regulatory pathway involving Smad4 deSUMOylation restrains Th17 pathogenicity.
- Targeting SENP2 may offer a novel therapeutic strategy for inflammatory colitis and other Th17-driven diseases.
